ARLZ - Aralez Pharmaceuticals Stock Price, News & Analysis

$1.65 0.18 (12.24 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$1.47
Today's Range$1.48 - $1.70
52-Week Range$0.95 - $5.31
Volume818,600 shs
Average Volume870,901 shs
Market Capitalization$98.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37

About Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ARLZ
CUSIP73941U10

Debt

Debt-to-Equity Ratio4.64%
Current Ratio1.00%
Quick Ratio0.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.27 million
Price / Sales2.03
Cash FlowN/A
Price / CashN/A
Book Value$0.88 per share
Price / Book1.88

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.69)
Net Income$-102,970,000.00
Net Margins-112.89%
Return on Equity-118.13%
Return on Assets-20.79%

Miscellaneous

Employees216
Outstanding Shares66,890,000

Frequently Asked Questions for Aralez Pharmaceuticals (NASDAQ:ARLZ)

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced its earnings results on Thursday, November, 9th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.02. The company earned $24.30 million during the quarter, compared to analysts' expectations of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The business's revenue for the quarter was up 78.7% on a year-over-year basis. During the same period last year, the company posted ($0.32) earnings per share. View Aralez Pharmaceuticals' Earnings History.

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

Where is Aralez Pharmaceuticals' stock going? Where will Aralez Pharmaceuticals' stock price be in 2017?

2 brokerages have issued twelve-month target prices for Aralez Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Aralez Pharmaceuticals' share price to reach $4.00 in the next year. View Analyst Ratings for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:

  • Arthur S. Kirsch, Independent Chairman of the Board (Age 63)
  • Andrew Ian Koven, President, Chief Business Officer (Age 58)
  • Adrian Adams, Chief Executive Officer, Director (Age 64)
  • Scott J. Charles, Chief Financial Officer, Senior Vice President (Age 41)
  • Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration (Age 45)
  • Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary (Age 42)
  • Mark A. Glickman, Chief Commercial Officer (Age 50)
  • James Patrick Tursi M.D., Chief Medical Officer (Age 51)
  • Kenneth B. Lee Jr., Lead Independent Director
  • Neal Franklin Fowler, Independent Director (Age 54)

Who owns Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.70%), JW Asset Management LLC (0.43%), Wells Fargo & Company MN (0.41%), Brown Advisory Securities LLC (0.26%) and Ballentine Partners LLC (0.12%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, John R Plachetka, Kenneth B Lee Jr, Robert Paul Harris, Scott J Charles and Seth Rudnick. View Institutional Ownership Trends for Aralez Pharmaceuticals.

Who sold Aralez Pharmaceuticals stock? Who is selling Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and JW Asset Management LLC. Company insiders that have sold Aralez Pharmaceuticals company stock in the last year include Andrew I Koven, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, Robert Paul Harris and Scott J Charles. View Insider Buying and Selling for Aralez Pharmaceuticals.

Who bought Aralez Pharmaceuticals stock? Who is buying Aralez Pharmaceuticals stock?

Aralez Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Brown Advisory Securities LLC, Wells Fargo & Company MN and Ballentine Partners LLC. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Kenneth B Lee Jr, Scott J Charles and Seth Rudnick. View Insider Buying and Selling for Aralez Pharmaceuticals.

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately $1.65.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of $98.32 million and generates $54.27 million in revenue each year. The company earns $-102,970,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Aralez Pharmaceuticals employs 216 workers across the globe.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected]


MarketBeat Community Rating for Aralez Pharmaceuticals (ARLZ)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aralez Pharmaceuticals (NASDAQ:ARLZ)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (142.42% upside)

Consensus Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Analysts' Ratings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Chardan CapitalLower Price TargetBuy -> Buy$5.50 -> $4.00HighView Rating Details
4/10/2017Bloom BurtonUpgradeAccumulate -> BuyMediumView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
3/16/2016Dundee SecuritiesLower Price TargetBuy$10.00 -> $9.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Earnings History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018        
11/9/2017Q3($0.39)($0.37)$22.87 million$24.30 millionViewN/AView Earnings Details
8/9/20176/30/2017($0.41)($0.42)$21.37 million$27.62 millionViewListenView Earnings Details
5/9/20173/31/2017($0.40)($0.42)$20.23 million$26.00 millionViewListenView Earnings Details
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.32)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.53)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.08$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.11$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.05$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.06)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aralez Pharmaceuticals (NASDAQ:ARLZ)
2017 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.43)($0.43)($0.43)
Q3 20171($0.46)($0.46)($0.46)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/21/2013special$1.7512/31/201312/11/201312/30/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (NASDAQ ARLZ)

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 23.54%
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017James Patrick TursiInsiderSell9,960$2.50$24,900.00View SEC Filing  
7/28/2017Scott J CharlesCFOSell10,804$1.25$13,505.00View SEC Filing  
6/23/2017Eric TrachtenbergInsiderSell7,720$1.33$10,267.60View SEC Filing  
6/15/2017Arthur S KirschDirectorBuy15,000$1.15$17,250.00View SEC Filing  
6/14/2017Arthur S KirschDirectorBuy50,000$1.17$58,500.00View SEC Filing  
6/5/2017Andrew I KovenInsiderSell161,906$1.28$207,239.68View SEC Filing  
5/23/2017Jason AryehDirectorSell388,685$1.44$559,706.40View SEC Filing  
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.25View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.00View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.00View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.00View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.00View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.00View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.00View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.00View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.00View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.16View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.40View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.00View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.48View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.25View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.00View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aralez Pharmaceuticals (NASDAQ ARLZ)

Source:
DateHeadline
Outside the Box: Why Washington’s tax plans for executive compensation are misguidedOutside the Box: Why Washington’s tax plans for executive compensation are misguided
www.marketwatch.com - November 15 at 5:40 AM
Edited Transcript of ARLZ earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of ARLZ earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 1:51 PM
Today’s Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage TherapeuticsToday’s Research Reports on Stocks to Watch: Aralez Pharmaceuticals and Sage Therapeutics
finance.yahoo.com - November 10 at 1:51 PM
Aralez Pharmaceuticals Inc. (ARLZ) Issues  Earnings ResultsAralez Pharmaceuticals Inc. (ARLZ) Issues Earnings Results
www.americanbankingnews.com - November 9 at 10:52 PM
Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third QuarterAralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter
finance.yahoo.com - November 9 at 5:11 PM
66 Biggest Movers From Yesterday | Benzinga - Benzinga66 Biggest Movers From Yesterday | Benzinga - Benzinga
www.benzinga.com - November 3 at 4:24 PM
Aralez Pharmaceuticals Inc. (ARLZ) Scheduled to Post Quarterly Earnings on ThursdayAralez Pharmaceuticals Inc. (ARLZ) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 1:28 AM
James Patrick Tursi Sells 9,960 Shares of Aralez Pharmaceuticals Inc. (ARLZ) StockJames Patrick Tursi Sells 9,960 Shares of Aralez Pharmaceuticals Inc. (ARLZ) Stock
www.americanbankingnews.com - October 4 at 10:42 PM
Aralez Pharmaceuticals (ARLZ) & Cadence Pharmaceuticals (CADX) Critical ComparisonAralez Pharmaceuticals (ARLZ) & Cadence Pharmaceuticals (CADX) Critical Comparison
www.americanbankingnews.com - September 29 at 6:24 AM
Outside the Box: Trump’s tax plan is one big step from realityOutside the Box: Trump’s tax plan is one big step from reality
www.marketwatch.com - September 28 at 10:24 PM
Outside the Box: Why the Trump tax plan’s fuzzy math​ doesn’t add upOutside the Box: Why the Trump tax plan’s fuzzy math​ doesn’t add up
www.marketwatch.com - September 26 at 4:56 PM
Analyzing Aralez Pharmaceuticals (ARLZ) and The CompetitionAnalyzing Aralez Pharmaceuticals (ARLZ) and The Competition
www.americanbankingnews.com - September 11 at 2:24 AM
Contrasting Eli Lilly and (LLY) and Aralez Pharmaceuticals (ARLZ)Contrasting Eli Lilly and (LLY) and Aralez Pharmaceuticals (ARLZ)
www.americanbankingnews.com - September 7 at 2:20 PM
ETFs with exposure to Aralez Pharmaceuticals, Inc. : September 5, 2017ETFs with exposure to Aralez Pharmaceuticals, Inc. : September 5, 2017
finance.yahoo.com - September 5 at 10:42 PM
Recent Developments in the Pharmaceutical IndustryRecent Developments in the Pharmaceutical Industry
www.prnewswire.com - September 5 at 5:38 PM
Outside the Box: Here’s how Republicans and Democrats can come together to fix health careOutside the Box: Here’s how Republicans and Democrats can come together to fix health care
www.marketwatch.com - August 23 at 6:10 AM
Eli Lilly and (LLY) versus Aralez Pharmaceuticals (ARLZ) Head to Head AnalysisEli Lilly and (LLY) versus Aralez Pharmaceuticals (ARLZ) Head to Head Analysis
www.americanbankingnews.com - August 10 at 2:38 PM
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Price Target Cut to $4.00 by Analysts at Chardan CapitalAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Price Target Cut to $4.00 by Analysts at Chardan Capital
www.americanbankingnews.com - August 10 at 2:16 PM
Edited Transcript of ARLZ earnings conference call or presentation 9-Aug-17 1:00pm GMTEdited Transcript of ARLZ earnings conference call or presentation 9-Aug-17 1:00pm GMT
finance.yahoo.com - August 9 at 9:15 PM
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Releases  Earnings Results, Misses Expectations By $0.01 EPSAralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - August 9 at 3:24 PM
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) to Release Earnings on WednesdayAralez Pharmaceuticals Inc (NASDAQ:ARLZ) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:10 AM
Aralez Pharmaceuticals Inc. (ARLZ) CFO Sells $13,505.00 in StockAralez Pharmaceuticals Inc. (ARLZ) CFO Sells $13,505.00 in Stock
www.americanbankingnews.com - July 28 at 7:50 PM
Aralez: A Quick Overview Of The Investment Thesis - Seeking AlphaAralez: A Quick Overview Of The Investment Thesis - Seeking Alpha
seekingalpha.com - July 25 at 8:57 PM
Should You Be Worried About Your Heartburn Medication Causing Dementia?Should You Be Worried About Your Heartburn Medication Causing Dementia?
www.forbes.com - July 22 at 3:38 AM
Aralez Pharmaceuticals Inc. (ARLZ) Short Interest UpdateAralez Pharmaceuticals Inc. (ARLZ) Short Interest Update
www.americanbankingnews.com - July 16 at 7:06 AM
ARLZ: Promising Early Data Following Launch of Zontivity®; VIMOVO® Patents UpheldARLZ: Promising Early Data Following Launch of Zontivity®; VIMOVO® Patents Upheld
finance.yahoo.com - July 10 at 9:04 PM
Aralez Pharmaceuticals (ARLZ) Presents At Jefferies 2017 Global Healthcare Conference - SlideshowAralez Pharmaceuticals (ARLZ) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 4:21 PM
Aralez Pharma (ARLZ) Launchs Zontivity in the US - StreetInsider.comAralez Pharma (ARLZ) Launchs Zontivity in the US - StreetInsider.com
www.streetinsider.com - June 7 at 3:47 PM
Form 4 Aralez Pharmaceuticals For: May 11 Filed by: Armstrong Jennifer LouForm 4 Aralez Pharmaceuticals For: May 11 Filed by: Armstrong Jennifer Lou
www.streetinsider.com - May 13 at 2:44 AM
Aralez Pharmaceuticals reports 1Q lossAralez Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 8:59 AM
Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders - PR Newswire (press release)Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 3 at 8:41 PM
Aralez Pharma (ARLZ) to Reduce Workforce by 32% as Part of Cost Savings Program - StreetInsider.comAralez Pharma (ARLZ) to Reduce Workforce by 32% as Part of Cost Savings Program - StreetInsider.com
www.streetinsider.com - April 7 at 8:04 AM
Why Did Aralezs CEO Buy 500,000 Shares On March 15?Why Did Aralez's CEO Buy 500,000 Shares On March 15?
seekingalpha.com - March 27 at 3:43 PM
Aralez Pharmaceuticals (ARLZ): Adrian Adams CEO Purchased 500,000 Shares Last Week: An Update And InterviewAralez Pharmaceuticals (ARLZ): Adrian Adams CEO Purchased 500,000 Shares Last Week: An Update And Interview
seekingalpha.com - March 25 at 8:36 PM
ARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - March 23 at 10:04 PM
Aralez Pharmaceuticals (ARLZ) CEO Adrian Adams on Q4 2016 Results - Earnings Call TranscriptAralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 3:32 PM
Mid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - BenzingaMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Benzinga
www.benzinga.com - March 14 at 5:49 AM
Why Aralez Pharmaceuticals Inc. Got Slaughtered TodayWhy Aralez Pharmaceuticals Inc. Got Slaughtered Today
www.fool.com - March 13 at 4:00 PM
BUZZ-US STOCKS ON THE MOVE-Intel, Kronos, Aethlon, Aralez, Ciber - NasdaqBUZZ-US STOCKS ON THE MOVE-Intel, Kronos, Aethlon, Aralez, Ciber - Nasdaq
www.nasdaq.com - March 13 at 3:43 PM
Mid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - NasdaqMid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares ... - Nasdaq
www.nasdaq.com - March 13 at 3:43 PM
Aralez Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET todayAralez Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today
biz.yahoo.com - March 13 at 3:43 PM
Aralez Reports Fourth Quarter And Full-Year 2016 Financial ResultsAralez Reports Fourth Quarter And Full-Year 2016 Financial Results
us.rd.yahoo.com - March 13 at 8:34 AM
ARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD DisclosuARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu
us.rd.yahoo.com - March 13 at 8:34 AM
Q4 2016 Aralez Pharmaceuticals Inc Earnings Release - Before Market OpenQ4 2016 Aralez Pharmaceuticals Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 13 at 8:34 AM
ARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive AgreementARALEZ PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 2 at 3:51 PM
Aralez Pharmaceuticals (ARLZ) Presents at RBC Capital Markets Global Healthcare Conference 2017-SlideshowAralez Pharmaceuticals (ARLZ) Presents at RBC Capital Markets Global Healthcare Conference 2017-Slideshow
seekingalpha.com - February 22 at 8:38 PM
Outside the Box: Trump’s tax reform looks like just another of his tweetsOutside the Box: Trump’s tax reform looks like just another of his tweets
www.marketwatch.com - February 16 at 7:54 PM
Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) to Ring The Nasdaq Stock Market Closing Bell - NasdaqAralez Pharmaceuticals Inc. (Nasdaq: ARLZ) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq
www.nasdaq.com - February 14 at 9:18 PM
Research Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma - PR Newswire (press release)Research Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma - PR Newswire (press release)
www.prnewswire.com - February 8 at 3:52 PM
Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen - TheStreet.comPremarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen - TheStreet.com
www.thestreet.com - January 27 at 9:34 PM

Social Media

Financials

Chart

Aralez Pharmaceuticals (NASDAQ ARLZ) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.